Menggang Yu, Ph.D.
Affiliations: | 2004 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Public Health, Statistics, Biostatistics BiologyGoogle:
"Menggang Yu"Cross-listing: PHTree
Parents
Sign in to add mentor| Jeremy M. G. Taylor | grad student | 2004 | University of Michigan | |
| (Joint longitudinal-survival-cure model with application in prostate cancer studies.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chen R, Yu M. (2020) Tailored optimal post-treatment surveillance for cancer recurrence. Biometrics |
| Galsky MD, Mortazavi A, Milowsky MI, et al. (2020) Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903091 |
| Phadke S, Yu M, Miller K, et al. (2020) Abstract OT2-06-02: Phase 2 trial with safety-run in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive HER2 negative breast cancer Cancer Research. 80 |
| Witek ME, Harari PM, Burr A, et al. (2020) A Pilot Study of Intra-Treatment MRI/PET to Define Favorable and Unfavorable Radiographic Signatures of Patients with p16-Positive Oropharynx Cancer International Journal of Radiation Oncology Biology Physics. 106: 1148-1149 |
| Yi Y, Ye T, Yu M, et al. (2019) Cox Regression with Survival-Time-Dependent Missing Covariate Values. Biometrics |
| Witt JS, Jagodinsky JC, Liu Y, et al. (2019) Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation. American Journal of Clinical Oncology |
| Zhao SG, Yu M, Spratt DE, et al. (2019) Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro-Oncology |
| Galsky MD, Pal SK, Mortazavi A, et al. (2019) Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. Journal of Clinical Oncology. 37: 4504-4504 |
| Kratz JD, Uboha NV, Lubner SJ, et al. (2018) Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1442-1450 |
| Huling J, Yu M, O'Malley AJ. (2018) Instrumental Variable Based Estimation Under the Semiparametric Accelerated Failure Time Model. Biometrics |